The paradigm of precision medicine implies that breast cancer treatment should be tailored based on inherent risk of recurrence and/or individual sensitivity to various chemotherapies. A recent trial of olaparib in women with a BRCA1/2 mutation provides supporting evidence for this paradigm and suggests that the identification of genetic variants at the time of diagnosis might benefit an increasing number of patients.

中文翻译：

---

辅助奥拉帕利——所有乳腺癌患者都应该进行基因检测吗？

精准医学的范式意味着应根据固有的复发风险和/或个体对各种化疗的敏感性来定制乳腺癌治疗。最近在 BRCA1/2 突变女性中进行的奥拉帕尼试验为这一范式提供了支持证据，并表明在诊断时鉴定遗传变异可能使越来越多的患者受益。